order retatrutide (LY3437943) | GCGR/GLP-1R/GIPR Agonist | CAS 2381089-83-2 Retatrutide for Weight Loss: TRIUMPH-1

In 2025, 56% of California covered workers are at firms that offer health benefits to part-time employees

Strengths Robust methodology using target trial emulation, reducing confounders

1 Weight loss results: Tirzepatide: approximately 12% body weight loss from baseline Dulaglutide 1.5 mg: approximately 5% body weight loss from baseline Difference: roughly 7 percentage points in favour of tirzepatide Blood sugar control: Tirzepatide: -1.73% HbA1c reduction Dulaglutide 1.5 mg: -0.90% HbA1c reduction Difference: approximately 0.83 percentage points in favour of tirzepatide Cardiovascular outcomes Both medications have demonstrated cardiovascular safety and benefit in people with type 2 diabetes

Furthermore, hydration helps with fiber digestion

(E) Identification of gld-2 as a potential PUF-8 target mRNA involved in three gene ontology (GO) terms

( 10.1210/en.2018-00004) [DOI] [PMC free article] [PubMed] [Google Scholar] 38.Yamamoto H, Lee CE, Marcus JN, Williams TD, Michael Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJet al